This study investigates whether intermittent hypoxia (IH) and physical activity (PA), either alone or in combination (simultaneously or sequentially), can improve cognitive function and brain health in middle-aged adults (50-65 years old). The hypothesis is that (1) each intervention alone (IHT or PA) provides cognitive benefits and (2) combining IHT with PA may yield additive or synergistic effects, particularly when administered simultaneously rather than sequentially. By comparing these distinct interventions, the study aims to determine which approach best preserves or enhances cognitive performance in middle-aged adults. Findings from this research may inform non-pharmacological strategies to promote healthy aging and reduce the risk of age-related cognitive decline.
Age range
50 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Cognitive Function: Montreal Cognitive Assessment (MoCA)
Timeframe: Baseline (Week 0),Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cerebral Oxygenation - Tissue Saturation Index (TSI)
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Biomarker Analysis- Brain-Derived Neurotrophic Factor (BDNF) Levels
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cerebral blood flow
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cognitive Function: Stroop Test
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cognitive Function: N-Back
Timeframe: Baseline (Week 0),Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cognitive Function:Operation Span Test Task
Timeframe: Baseline (Week 0),Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cognitive Function: The Trail Making Test
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cerebral Oxygenation - Oxyhemoglobin (O₂Hb)
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cerebral Oxygenation - Deoxyhemoglobin (HHb)
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Cerebral Oxygenation - Total Hemoglobin (tHb)
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Biomarker Analysis-Vascular Endothelial Growth Factor (VEGF) Levels
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Biomarker Analysis -Irisin Levels
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)
Biomarker Analysis-Hypoxia-Inducible Factor-1 Alpha (HIF-1α) Pathway Activation
Timeframe: Baseline (Week 0), Week 1 (after 3 sessions), Week 6 (post-intervention, after session 18)